JPWO2022243285A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022243285A5 JPWO2022243285A5 JP2023571283A JP2023571283A JPWO2022243285A5 JP WO2022243285 A5 JPWO2022243285 A5 JP WO2022243285A5 JP 2023571283 A JP2023571283 A JP 2023571283A JP 2023571283 A JP2023571283 A JP 2023571283A JP WO2022243285 A5 JPWO2022243285 A5 JP WO2022243285A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- pharmaceutical composition
- polymer
- disease
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163189449P | 2021-05-17 | 2021-05-17 | |
| US63/189,449 | 2021-05-17 | ||
| PCT/EP2022/063269 WO2022243285A1 (en) | 2021-05-17 | 2022-05-17 | Formulations of psilocybin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024522065A JP2024522065A (ja) | 2024-06-11 |
| JPWO2022243285A5 true JPWO2022243285A5 (https=) | 2025-03-25 |
| JP2024522065A5 JP2024522065A5 (https=) | 2025-03-25 |
Family
ID=82019233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023571283A Pending JP2024522065A (ja) | 2021-05-17 | 2022-05-17 | シロシビンの製剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240261306A1 (https=) |
| EP (1) | EP4340809A1 (https=) |
| JP (1) | JP2024522065A (https=) |
| KR (1) | KR20240009433A (https=) |
| AU (1) | AU2022277515B2 (https=) |
| CA (1) | CA3216799A1 (https=) |
| WO (1) | WO2022243285A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240074434A1 (en) * | 2019-04-12 | 2024-03-07 | Jeffrey Hanson Robbins | Composition including effervescent agents, biostimulant, nutrient, and pesticide |
| AU2021268204A1 (en) | 2020-05-08 | 2022-12-08 | Psilera Inc. | Novel compositions of matter and pharmaceutical compositions |
| JP2024545787A (ja) | 2021-12-30 | 2024-12-11 | アタイ セラピューティクス， インコーポレイテッド | 一酸化窒素送達剤としてのジメチルトリプタミン類似体 |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| CA3247344A1 (en) * | 2022-06-09 | 2023-12-14 | Diamond Therapeutics Inc. | AMORPHIC PSILOCYBIN (A-POLYMORPHIC) |
| US20250360148A1 (en) * | 2022-06-22 | 2025-11-27 | Cybin Irl Limited | Solid dispersions of psilocybin |
| WO2024031152A1 (en) * | 2022-08-12 | 2024-02-15 | Woke Pharmaceuticals Pty Ltd | Process for improving powder flow characteristics of a crystalline compound |
| EP4615444A1 (en) * | 2022-11-07 | 2025-09-17 | Natural Medtech Pty Ltd | Tryptamine formulations and uses thereof |
| EP4720039A2 (en) * | 2023-05-24 | 2026-04-08 | Psilera Inc. | Formulations containing tryptamine derivatives and uses thereof |
| WO2025080937A1 (en) * | 2023-10-11 | 2025-04-17 | University Of Padova | Compositions with psilocybin and psilocin derivatives |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| US20020017295A1 (en) | 2000-07-07 | 2002-02-14 | Weers Jeffry G. | Phospholipid-based powders for inhalation |
| US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US8585580B2 (en) * | 2008-01-23 | 2013-11-19 | Ams Research Corporation | Inflatable medical implant system |
| JP2013103899A (ja) * | 2011-11-11 | 2013-05-30 | Fuji Chem Ind Co Ltd | 難溶性薬物の新規な固体分散体 |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| JP7502308B2 (ja) * | 2019-01-18 | 2024-06-18 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 固体投与形態を製造する方法および固体投与形態 |
| KR20220009954A (ko) * | 2019-04-17 | 2022-01-25 | 컴퍼스 패쓰파인더 리미티드 | 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법 |
| GB201907871D0 (en) * | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| WO2021003467A1 (en) * | 2019-07-04 | 2021-01-07 | Sw Holdings, Inc. | Metered dosing compositions and methods of use of psychedelic compounds |
| US20210015738A1 (en) * | 2019-07-17 | 2021-01-21 | Concept Matrix Solutions | Oral dissolvable film containing psychedelic compound |
| US11000534B1 (en) * | 2020-10-08 | 2021-05-11 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psilocybin and uses thereof |
-
2022
- 2022-05-17 JP JP2023571283A patent/JP2024522065A/ja active Pending
- 2022-05-17 AU AU2022277515A patent/AU2022277515B2/en active Active
- 2022-05-17 US US18/561,152 patent/US20240261306A1/en active Pending
- 2022-05-17 WO PCT/EP2022/063269 patent/WO2022243285A1/en not_active Ceased
- 2022-05-17 CA CA3216799A patent/CA3216799A1/en active Pending
- 2022-05-17 EP EP22729558.1A patent/EP4340809A1/en active Pending
- 2022-05-17 KR KR1020237041239A patent/KR20240009433A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2022243285A5 (https=) | ||
| JP6758677B2 (ja) | グルタルイミド誘導体を含む医薬組成物、及び好酸球性疾患を処置するためのその適用 | |
| CN111094242B (zh) | 用于治疗与nlrp活性相关的病症的化合物和组合物 | |
| TWI535701B (zh) | 使用選擇性ｂｃｌ－２抑制劑之治療方法 | |
| JP2865872B2 (ja) | ３−（５−テトラゾリル−ベンジル）アミノ−ピペリジン誘導体およびタキキニンのアンタゴニスト | |
| CN111417622A (zh) | 用于治疗与nlrp活性相关的病症的磺胺类及其组合物 | |
| DE69508093T2 (de) | Substituierte piperidine für die behandlung von allergischen krankheiten | |
| IL297492A (en) | Deuterated tryptamine derivatives and methods of use | |
| JP5506776B2 (ja) | 新規ｐ２ｘ７ｒ拮抗薬及びその使用法 | |
| JP2013537887A5 (https=) | ||
| CN101341147A (zh) | 具有cxcr3拮抗剂活性的取代的杂环化合物 | |
| JPH0733385B2 (ja) | 物質ｐの拮抗薬としてのｎ−アルキルキヌクリジニウム塩 | |
| JPWO2021234608A5 (https=) | ||
| JP2003506365A (ja) | ベンゾフリルピペラジンおよびベンゾフリルホモピペラジン：セロトニンアゴニスト | |
| CN1420776A (zh) | 环氧合酶－2活性的抑制 | |
| CN108698991B (zh) | 2-氧代吲哚化合物 | |
| JPWO2023036473A5 (https=) | ||
| Chen et al. | Role of interleukin-6 family cytokines in organ fibrosis | |
| JPWO2022038170A5 (https=) | ||
| WO2021194991A1 (en) | Use of losmapimod for treatment of covid-19 | |
| JPH07502738A (ja) | 新規なアデノシン誘導体，その製造方法およびそれを含有する医薬組成物 | |
| JPWO2022038171A5 (https=) | ||
| RU2009136331A (ru) | Индоловые и бензотиофеновые соединения в качестве модуляторов гистаминового н3-рецептора | |
| JPWO2023156453A5 (https=) | ||
| Wei et al. | CXCR1/CXCR2 antagonism is effective in pulmonary defense against Klebsiella pneumoniae infection |